Evidence map›Paper›PMID 34452512›Full record

ArticleViruses2021

SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic.

Anna Y Popova, Viacheslav S Smirnov, Elena E Andreeva, Elena A Babura, Sergey V Balakhonov, Natalia S Bashketova, Svetlana A Bugorkova, Maxim V Bulanov, Natalia N Valeullina, Viacheslav V Vetrov and 24 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. SARS-CoV-2 herd immunity of the Kyrgyz population in 2021.Medical microbiology and immunology · 2022
    Article
  12. Article
  13. Seropositivity of SARS-CoV-2 in the Population of Kazakhstan: A Nationwide Laboratory-Based Surveillance.International journal of environmental research and public health · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors at 9 institutions in 1 country.

Anna Y PopovaFederal Service for Supervision of Consumer Rights Protection and Human Welfare, 127994 Moscow, Russia.
Viacheslav S SmirnovSaint Petersburg Pasteur Institute, 197101 St. Petersburg, Russia.ORCID 0000-0002-2723-1496
Elena E AndreevaRospotrebnadzor Administration in Moscow, 129626 Moscow, Russia.
Elena A BaburaRospotrebnadzor Administration in the Kaliningrad Region, 236040 Kaliningrad, Russia.
Sergey V BalakhonovIrkutsk Research Anti-Plague Institute, 664047 Irkutsk, Russia.
Natalia S BashketovaRospotrebnadzor Administration in St. Petersburg, 191025 St. Petersburg, Russia.
Svetlana A BugorkovaRussian Research Anti-Plague Institute "Microbe", 410005 Saratov, Russia.
Maxim V BulanovCenter for Hygiene and Epidemiology of the Vladimir Region, 600005 Vladimir, Russia.
Natalia N ValeullinaRospotrebnadzor Administration in the Chelyabinsk Region, 454091 Chelyabinsk, Russia.
Viacheslav V VetrovSaint Petersburg Pasteur Institute, 197101 St. Petersburg, Russia.
Dmitriy V GoryaevRospotrebnadzor Administration in the Krasnoyarsk Territory, 660049 Krasnoyarsk, Russia.
Tatyana N DetkovskayaRospotrebnadzor Administration in the Primorsky Krai, 690950 Vladivostok, Russia.
Elena B EzhlovaFederal Service for Supervision of Consumer Rights Protection and Human Welfare, 127994 Moscow, Russia.
Natalia N ZaitsevaNizhny Novgorod I. N. Blokhina Research Institute of Epidemiology and Microbiology, 603950 Nizhny Novgorod, Russia.
Olga A IstorikRospotrebnadzor Administration in the Leningrad Region, 192029 St. Petersburg, Russia.
Irina V KovalchukRospotrebnadzor Administration in the Stavropol Territory, 355008 Stavropol, Russia.
Dmitriy N KozlovskikhRospotrebnadzor Administration in the Sverdlovsk Region, 620078 Yekaterinburg, Russia.
Svetlana Y KombarovaG. N. Gabrichevsky Moscow Research Institute for Epidemiology and Microbiology, 125212 Moscow, Russia.
Olga P KurganovaRospotrebnadzor Administration in the Amur Region, 675002 Blagoveshchensk, Russia.
Alexander E LomovtsevRospotrebnadzor Administration in the Tula Region, 300045 Tula, Russia.
Lena A LukichevaRospotrebnadzor Administration in the Murmansk Region, 183038 Murmansk, Russia.
Ludmila V LyalinaSaint Petersburg Pasteur Institute, 197101 St. Petersburg, Russia.
Albina A MelnikovaFederal Service for Supervision of Consumer Rights Protection and Human Welfare, 127994 Moscow, Russia.
Olga M MikailovaRospotrebnadzor Administration in the Moscow Region, 141014 Mytishchi, Moscow Region, Russia.
Alexei K NoskovRostov-on-Don Research Anti-Plague Institute, 344000 Rostov-on-Don, Russia.
Ludmila N NoskovaRospotrebnadzor Administration for the Astrakhan Region, 414057 Astrakhan, Russia.
Elena E OgleznevaRospotrebnadzor Administration in the Belgorod Region, 308023 Belgorod, Russia.
Tatyana P OsmolovskayaRospotrebnadzor Administration in the Krasnodar Territory, 350000 Krasnodar, Russia.
Marina A PatyashinaRospotrebnadzor Administration in the Republic of Tatarstan, 420111 Kazan, Russia.
Natalia A PenkovskayaRospotrebnadzor Administration in the Republic of Crimea, 295034 Simferopol, Russia.
Lada V SamoilovaRospotrebnadzor Administration in the Novosibirsk Region, 630132 Novosibirsk, Russia.
Tatyana F StepanovaTyumen Research Institute of Regional Infectious Pathology, 625026 Tyumen, Russia.
Olga E TrotsenkoKhabarovsk Research Institute of Epidemiology and Microbiology, 680000 Khabarovsk, Russia.
Areg A TotolianSaint Petersburg Pasteur Institute, 197101 St. Petersburg, Russia.
Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing · RUSaint Petersburg Pasteur Institute · RUBelgorod Law Institute of the Russian Interior Ministry · RUGabrichevsky Institute of Epidemiology and Microbiology · RUKhabarovsk Scientific Research Institute of Epidemiology and Microbiology · RUNizhniy Novgorod Research Institute of Epidemiology and Microbiology named after Academician I.N. Blokhina · RUResearch Institute of Agriculture of Crimea · RURostov-on-Don Anti-plague Institute Rospotrebnadzor · RURussian Scientific Research Institute Microbe · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The SARS-CoV-2 pandemic, which came to Russia in March 2020, is accompanied by morbidity level changes and can be tracked using serological monitoring of a representative population sample from Federal Districts (FDs) and individual regions. In a longitudinal cohort study conducted in 26 model regions of Russia, distributed across all FDs, we investigated the distribution and cumulative proportions of individuals with antibodies (Abs) to the SARS-CoV-2 nucleocapsid antigen (Ag), in the period from June to December 2020, using a three-phase monitoring process. In addition, during the formation of the cohort of volunteers, the number of seropositive convalescents, persons who had contact with patients or COVID-19 convalescents, and the prevalence of asymptomatic forms of infection among seropositive volunteers were determined. According to a uniform methodology, 3 mL of blood was taken from the examined individuals, and plasma was separated, from which the presence of Abs to nucleocapsid Ag was determined on a Thermo Scientific Multiascan FC device using the "ELISA anti-SARS-CoV-2 IgG" reagent set (prod. Scientific Center for Applied Microbiology and Biotechnology), in accordance with the developer's instructions. Volunteers (74,158) were surveyed and divided into seven age groups (1-17, 18-29, 30-39, 40-49, 59-59, 60-69, and 70+ years old), among whom 14,275 were identified as having antibodies to SARS-CoV-2. The average percent seropositive in Russia was 17.8% (IQR: 8.8-23.2). The largest proportion was found among children under 17 years old (21.6% (IQR: 13.1-31.7). In the remaining groups, seroprevalence ranged from 15.6% (IQR: 8-21.1) to 18.0% (IQR: 13.4-22.6). During monitoring, three (immune) response groups were found: (A) groups with a continuous increase in the proportion of seropositive; (B) those with a slow rate of increase in seroprevalence; and (C) those with a two-phase curve, wherein the initial increase was replaced by a decrease in the percentage of seropositive individuals. A significant correlation was revealed between the number of COVID-19 convalescents and contact persons, and between the number of contacts and healthy seropositive volunteers. Among the seropositive volunteers, more than 93.6% (IQR: 87.1-94.9) were asymptomatic. The results show that the COVID-19 pandemic is accompanied by an increase in seroprevalence, which may be important for the formation of herd immunity.

Indexed as

AdolescentAdultAgedAntibodies, ViralAsymptomatic InfectionsChildChild, PreschoolCoronavirus Nucleocapsid ProteinsCOVID-19HumansImmunity, HerdImmunoglobulin GInfantLongitudinal StudiesMiddle AgedPandemicsAntibodies, ViralCoronavirus Nucleocapsid ProteinsImmunoglobulin Gnucleocapsid phosphoprotein, SARS-CoV-2Phosphoproteinsasymptomatic formCOVID-19herd immunitypopulationRussiaSARS-CoV-2

Identifiers

PMID34452512
PMCPMC8402751
OpenAlexW3193760090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.